GlassScriptPhysician profile
Lloyd A Shabazz
NPI 1720082183
$15,703.62
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $937 · 2021: $600.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $10,006.41 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $3,896.03 | 2019 | |
| Pfizer INC. | $940.00 | 2019-2021 | |
| Janssen Biotech, INC. | $233.49 | 2019-2020 | |
| Genzyme Corporation | $155.40 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $134.72 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $46.76 | 2019-2020 | |
| Daiichi Sankyo INC. | $41.90 | 2020 | |
| Astellas Pharma US INC | $40.67 | 2019-2020 | |
| Amgen INC. | $38.14 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $37.06 | 2020 | |
| Puma Biotechnology, INC. | $33.15 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $21.35 | 2020 | |
| Grifols USA, LLC | $20.37 | 2019 | |
| Karyopharm Therapeutics INC. | $19.70 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $16.68 | 2020 | |
| Genentech USA, INC. | $14.79 | 2019 | |
| Bioverativ Therapeutics INC. | $7.00 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Research and ownership
$161,034.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Shabazz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.